MOHAMAD AL JABBAN: Open Payments
NPI 1831291764 · ORLANDO, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,798 in 150 payments from 23 companies in 2025. Trend: 2023 $2,192 · 2024 $1,969 · 2025 $2,798
Food & beverage: $2,798
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $488 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 22 | $367 |
| Amgen Inc. | 21 | $285 |
| AstraZeneca Pharmaceuticals LP | 11 | $273 |
| Novartis Pharmaceuticals Corporation | 11 | $196 |
| Bayer Healthcare Pharmaceuticals Inc. | 9 | $152 |
| Novo Nordisk Inc | 9 | $147 |
| Sumitomo Pharma America, Inc. | 8 | $146 |
| PFIZER INC. | 5 | $112 |
| Otsuka America Pharmaceutical, Inc. | 5 | $101 |
Products named: CAPLYTA, RINVOQ, BREZTRI, COSENTYX, REXULTI, Kerendia, GEMTESA, OTEZLA.
Industry payments across FL — which companies pay providers there.
